Volume 84, Issue 2_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



We assessed the safety, tolerability, and immunogenicity of a mixture of three synthetic peptides derived from the circumsporozoite protein formulated in Montanide ISA 720 or Montanide ISA 51. Forty healthy malaria-naive volunteers were allocated to five experimental groups (A–E): four groups (A–D) were immunized intramuscularly with 50 and 100 μg/dose injections of a mixture of N, R, and C peptides formulated in the two different adjuvants at 0, 2, and 4 months and one group was administered placebo. Vaccines were immunogenic, safe, well tolerated, and no serious adverse events related to the vaccine occurred. Seroconversion occurred in > 90% of the vaccines and antibodies recognized the sporozoite protein on immunofluorescent antibody test. Vaccines in Montanide ISA 51 showed a higher sporozoite protein recognition and interferon production. Results encourage further testing of the vaccine protective efficacy.


Article metrics loading...

Loading full text...

Full text loading...



  1. Nussenzweig RS, Vanderberg J, Most H, Orton C, , 1967. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei . Nature 216: 160162.[Crossref]
  2. Clyde DF, , 1990. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971–75. Bull World Health Organ 68 (Suppl): 912.
  3. Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H, Losonsky G, Hollingdale M, Sztein M, Levine M, Nussenzweig RS, Clyde D, Edelman R, , 1991. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 45: 539547.
  4. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL, , 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 11551164.[Crossref]
  5. Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, Grau GE, Hollingdale MR, Ballou WR, Gordon DM, , 1993. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 49: 166173.
  6. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F, , 1989. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341: 323326.[Crossref]
  7. Tsuji M, Romero P, Nussenzweig RS, Zavala F, , 1990. CD4+ cytolytic T cell clone confers protection against murine malaria. J Exp Med 172: 13531357.[Crossref]
  8. Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, BenMohamed L, Slierendregt B, Eling W, Van Belkum A, Dubreuil G, Meis JF, Guerin-Marchand C, Cayphas S, Cohen J, Gras-Masse H, Druilhe P, , 2000. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 6: 12581263.[Crossref]
  9. Chappel JA, Rogers WO, Hoffman SL, Kang AS, , 2004. Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor. Malar J 3: 28.[Crossref]
  10. Hoffman SL, Nussenzweig V, Sadoff JC, Nussenzweig RS, , 1991. Progress toward malaria preerythrocytic vaccines. Science 252: 520521.[Crossref]
  11. Taylor-Robinson AW, , 2003. Immunity to liver stage malaria: considerations for vaccine design. Immunol Res 27: 5370.[Crossref]
  12. Cerami C, Frevert U, Sinnis P, Takacs B, Clavijo P, Santos MJ, Nussenzweig V, , 1992. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 70: 10211033.[Crossref]
  13. Frevert U, Sinnis P, Cerami C, Shreffler W, Takacs B, Nussenzweig V, , 1993. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med 177: 12871298.[Crossref]
  14. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M, , 1980. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207: 7173.[Crossref]
  15. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M, , 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336: 8691.[Crossref]
  16. Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G, Kester KE, Heppner DG, Krzych U, , 2003. Protective immunity induced with malaria vaccine, RTS,S is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 171: 69616967.[Crossref]
  17. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Jr Hall T, Wellde BT, White K, Sun P, Schwenk R, Krzych U, Delchambre M, Voss G, Dubois MC, Gasser RA, Jr Dowler MG, O'Brien M, Wittes J, Wirtz R, Cohen J, Ballou WR, , 2007. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine 25: 53595366.[Crossref]
  18. Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, Gordon DM, Schwenk RJ, Krzych U, Holland CA, Richmond G, Dowler MG, Williams J, Wirtz RA, Tornieporth N, Vigneron L, Delchambre M, Demoitie MA, Ballou WR, Cohen J, Heppner DG, Jr, 2008. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26: 21912202.[Crossref]
  19. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T, , 2001. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358: 19271934.[Crossref]
  20. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J, , 2004. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364: 14111420.[Crossref]
  21. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, Demoitie MA, Stallaert JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, von Seidlein L, , 2008. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359: 25212532.[Crossref]
  22. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, Omari S, Urassa A, Mshinda H, Jumanne A, Salim N, Shomari M, Aebi T, Schellenberg DM, Carter T, Villafana T, Demoitie MA, Dubois MC, Leach A, Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M, , 2008. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 359: 25332544.[Crossref]
  23. Herrera S, Bonelo A, Perlaza BL, Valencia AZ, Cifuentes C, Hurtado S, Quintero G, Lopez JA, Corradin G, Arevalo-Herrera M, , 2004. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int J Parasitol 34: 15351546.[Crossref]
  24. Herrera S, Perlaza BL, Bonelo A, Arevalo-Herrera M, , 2002. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. Int J Parasitol 32: 16251635.[Crossref]
  25. Herrera S, Bonelo A, Perlaza BL, Fernandez OL, Victoria L, Lenis AM, Soto L, Hurtado H, Acuna LM, Velez JD, Palacios R, Chen-Mok M, Corradin G, Arevalo-Herrera M, , 2005. Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 73: 39.
  26. Pye D, Vandenberg KL, Dyer SL, Irving DO, Goss NH, Woodrow GC, Saul A, Alving CR, Richards RL, Ballou WR, Wu MJ, Skoff K, Anders RF, , 1997. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine 15: 10171023.[Crossref]
  27. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo J, , 2007. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25: 21202127.[Crossref]
  28. O'Hagan DT, Valiante NM, , 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2: 727735.[Crossref]
  29. Aucouturier J, Ascarateil S, Dupuis L, , 2006. The use of oil adjuvants in therapeutic vaccines. Vaccine 24 (Suppl 2): S2-4445.
  30. Arevalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincon A, Saul A, Mu J, Long C, Miller L, Herrera S, , 2005. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. Am J Trop Med Hyg 73: 3237.
  31. Arevalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R, Herrera S, , 2005. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am J Trop Med Hyg 73: 2531.
  32. Valderrama-Aguirre A, Quintero G, Gomez A, Castellanos A, Perez Y, Mendez F, Arevalo-Herrera M, Herrera S, , 2005. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg 73: 1624.
  33. Bell BA, Wood JF, Bansal R, Ragab H, Cargo J, 3rd Washington MA, Wood CL, Ware LA, Ockenhouse CF, Yadava A, , 2009. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax . Vaccine 27: 14481453.[Crossref]
  34. Hu J, Chen Z, Gu J, Wan M, Shen Q, Kieny MP, He J, Li Z, Zhang Q, Reed ZH, Zhu Y, Li W, Cao Y, Qu L, Cao Z, Wang Q, Liu H, Pan X, Huang X, Zhang D, Xue X, Pan W, , 2008. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS ONE 3: e1952.[Crossref]
  35. Malkin E, Hu J, Li Z, Chen Z, Bi X, Reed Z, Dubovsky F, Liu J, Wang Q, Pan X, Chen T, Giersing B, Xu Y, Kang X, Gu J, Shen Q, Tucker K, Tierney E, Pan W, Long C, Cao Z, , 2008. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 26: 68646873.[Crossref]
  36. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP, , 2008. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 3: e2636.[Crossref]
  37. Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, Imoukhuede E, Jepsen S, Ofori-Anyinam O, Faber B, Kocken CH, Arnold M, Walraven V, Teelen K, Roeffen W, de Mast Q, Ballou WR, Cohen J, Dubois MC, Ascarateil S, van der Ven A, Thomas A, Sauerwein R, , 2008. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS ONE 3: e3960.[Crossref]
  38. Atherton E, Logan CJ, Sheppard RC, , 1988. Peptide synthesis. II. Procedures for solid phase synthesis using N-fluorenylmethoxycarbonylamino-acids on polyamide supports: synthesis of substance P and of acyl carrier protein 65–74 decapeptide. J Chem Soc Perkin Trans 1: 538548.
  39. Verdini A, Terenzi S, Brossard V, Roggero M, Corradin G, , 2008. Oxidative folding of synthetic polypeptides S-protected as tert-butylthio derivatives. J Pept Sci 14: 12711282.[Crossref]
  40. National Cancer Institute, 1998. Common Toxicity Criteria, version 2.0, 130.
  41. WHO, 2002. Workbook for Clinical Monitor. TDR/PRD Standard Operating Procedures (SOPs) and Guidelines. Geneva, Switzerland: World Health Organization, 281288.
  42. Arevalo-Herrera M, Roggero MA, Gonzalez JM, Vergara J, Corradin G, Lopez JA, Herrera S, , 1998. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. Ann Trop Med Parasitol 92: 539551.[Crossref]
  43. Moore AC, Hutchings CL, , 2007. Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity. Expert Rev Vaccines 6: 111121.[Crossref]
  44. Wang R, Charoenvit Y, Daly TM, Long CA, Corradin G, Hoffman SL, , 1996. Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine. Immunol Lett 53: 8393.[Crossref]
  45. Hutchings CL, Birkett AJ, Moore AC, Hill AV, , 2007. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect Immun 75: 58195826.[Crossref]
  46. Herrera S, Gomez A, Vera O, Vergara J, Valderrama-Aguirre A, Maestre A, Mendez F, Wang R, Chitnis CE, Yazdani SS, Arevalo-Herrera M, , 2005. Antibody response to Plasmodium vivax antigens in Fy-negative individuals from the Colombian Pacific coast. Am J Trop Med Hyg 73: 4449.
  47. Reed SG, Bertholet S, Coler RN, Friede M, , 2009. New horizons in adjuvants for vaccine development. Trends Immunol 30: 2332.[Crossref]
  48. Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F, , 2005. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 73: 80178026.[Crossref]
  49. Saul A, Lawrence G, Allworth A, Elliott S, Anderson K, Rzepczyk C, Martin LB, Taylor D, Eisen DP, Irving DO, Pye D, Crewther PE, Hodder AN, Murphy VJ, Anders RF, , 2005. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23: 30763083.[Crossref]
  50. Gregson AL, Oliveira G, Othoro C, Calvo-Calle JM, Thorton GB, Nardin E, Edelman R, , 2008. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS ONE 3: e1556.[Crossref]
  51. Tapchaisri P, Dekumyoy P, Asavanich A, Chongsa-nguan M, Tharavanij S, Harinasuta T, , 1985. Antibodies against circumsporozoite proteins of Plasmodium falciparum induced by natural infection. Southeast Asian J Trop Med Public Health 16: 355364.
  52. Kremsner PG, Neifer S, Zotter GM, Bienzle U, Rocha RM, Maracic M, Clavijo P, Nussenzweig RS, Cochrane AH, , 1992. Prevalence and level of antibodies to the circumsporozoite proteins of human malaria parasites, including a variant of Plasmodium vivax, in the population of two epidemiologically distinct areas in the state of Acre, Brazil. Trans R Soc Trop Med Hyg 86: 2327.[Crossref]
  53. Arévalo-Herrera M, Vera O, Castellanos A, Cespedes N, Soto L, Corradin G, Herrera S, , 2011. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in Montanide ISA 720 and Montanide ISA 51 adjuvants. Am J Trop Med Hyg 84 (Suppl 2): 2127.[Crossref]
  54. Garraud O, Mahanty S, Perraut R, , 2003. Malaria-specific antibody subclasses in immune individuals: a key source of information for vaccine design. Trends Immunol 24: 3035.[Crossref]
  55. Arevalo-Herrera M, Valencia AZ, Vergara J, Bonelo A, Fleischhauer K, Gonzalez JM, Restrepo JC, Lopez JA, Valmori D, Corradin G, Herrera S, , 2002. Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria. Parasite Immunol 24: 161169.[Crossref]
  56. Bongfen SE, Ntsama PM, Offner S, Smith T, Felger I, Tanner M, Alonso P, Nebie I, Romero JF, Silvie O, Torgler R, Corradin G, , 2009. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27: 328335.[Crossref]
  57. Coppi A, Pinzon-Ortiz C, Hutter C, Sinnis P, , 2005. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med 201: 2733.[Crossref]

Data & Media loading...

  • Received : 02 Sep 2009
  • Accepted : 02 Apr 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error